• Viking Therapeutics expects data from two Phase 3 VANQUISH trials of injectable obesity drug VK2735 in the second half of 2027.
• VANQUISH-1 enrolled more than 4,500 adults; VANQUISH-2 enrolled approximately 1,000 adults with type 2 diabetes.
• Oral VK2735 is in Phase 3 SUNRISE trials, with a Phase 1 maintenance study initiated.
• Amylin agonist VK3019 entered Phase 1 development in the second quarter of 2026.
• Partnering discussions remain ongoing for MASH candidate VK2809 following successful completion of its Phase 2b VOYAGE trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.